Free Trial
→ ZENA Surges: 558% Revenue Growth Fuels Breakout Small-Cap Narrative! (From Equiscreen) (Ad)tc pixel Free CDTX Stock Alerts

This company has been marked as potentially delisted and may not be actively trading.

Cidara Therapeutics (CDTX) Short Interest Ratio & Short Volume

Cidara Therapeutics logo
Compare

Cidara Therapeutics Short Interest Overview

As of December 31, 2025, Cidara Therapeutics (CDTX) had a short interest of 1.88 million shares sold short, representing 6.23% of the public float. This marks a -6.78% decrease in short interest since the prior report. The short interest ratio (days to cover) is 2.2, meaning it would take 2.2 days of the average trading volume of 928,762 shares to cover all short positions.

Current Short Interest
1,882,216 shares
Previous Short Interest
2,019,038 shares
Change Vs. Previous Month
-6.78%
Dollar Volume Sold Short
$415.76 million
Short Interest Ratio
2.2 Days to Cover
Last Record Date
December 31, 2025
Outstanding Shares
31,439,000 shares
Short Percent of Float
6.23%
Today's Trading Volume
2,691,000 shares
Average Trading Volume
928,762 shares
Today's Volume Vs. Average
290%
Short Selling Cidara Therapeutics?
A Guide To High-Short-Interest Stocks

Sign up to receive the latest short interest report for Cidara Therapeutics and its competitors with MarketBeat's FREE newsletter.

Get Report
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Short Interest History
Short Interest ChartDays to Cover ChartShort Percent of Float Chart

CDTX Short Interest Over Time

CDTX Days to Cover Over Time

CDTX Percentage of Float Shorted Over Time

Cidara Therapeutics Tesla Short Interest History & Recent Changes

Export
Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
12/31/20251,882,216 shares $415.76 million -6.8%6.2%2.23 $220.89
12/15/20252,019,038 shares $444.39 million -4.5%7.0%1.92 $220.10
11/28/20252,114,487 shares $464.81 million -35.9%7.3%1.04 $219.82
11/14/20253,297,917 shares $717.99 million +3.0%11.4%1.48 $217.71
10/31/20253,203,532 shares $349.95 million +7.4%13.7%3.74 $109.24
10/15/20252,980,000 shares $314.75 million -2.3%15.4%3.9 $105.62
9/30/20253,050,000 shares $292.07 million +39.3%15.8%4.1 $95.76
9/15/20252,190,000 shares $146.53 million +1.9%11.3%2.7 $66.91
8/31/20252,150,000 shares $140.59 million +3.4%11.8%2.7 $65.39
8/15/20252,080,000 shares $135.64 million -5.0%11.1%2.8 $65.21
7/31/20252,190,000 shares $138.65 million -3.5%10.9%3.2 $63.31
7/15/20252,270,000 shares $116.88 million +41.0%13.0%3.5 $51.49
6/30/20251,610,000 shares $78.42 million +148.3%12.3%2.9 $48.71
6/15/2025648,300 shares $14.81 million +36.7%8.5%1.7 $22.84
5/31/2025474,300 shares $10.46 million +6.5%6.2%2.8 $22.06
5/15/2025445,300 shares $9.37 million -1.6%5.8%2.9 $21.04
4/30/2025452,500 shares $9.45 million -5.7%5.6%3.4 $20.89
4/15/2025480,000 shares $9.60 million +2.1%7.0%3.5 $20.00
3/31/2025470,300 shares $10.13 million +62.2%6.9%3.4 $21.54
3/15/2025289,900 shares $6.39 million +21.9%4.2%2.4 $22.05
2/28/2025237,800 shares $5.92 million +30.7%3.5%2.4 $24.90
2/15/2025182,000 shares $4.36 million +31.5%2.6%1.8 $23.94
1/31/2025138,400 shares $2.57 million +27.6%3.0%1.5 $18.58
1/15/2025108,500 shares $2.22 million +40.7%2.3%1.4 $20.42
12/31/202477,100 shares $2.07 million +113.6%1.7%1.2 $26.88
12/15/202436,100 shares $825.97 thousand -31.6%1.2%0.8 $22.88
11/30/202452,800 shares $1.07 million +6.0%1.2%1.4 $20.21
11/15/202449,800 shares $715.63 thousand -22.9%0.9%1.5 $14.37
10/31/202464,600 shares $839.80 thousand -3.6%1.1%3.2 $13.00
10/15/202467,000 shares $681.39 thousand -20.1%1.1%3.4 $10.17
9/30/202483,800 shares $900.85 thousand +28.7%1.4%4.1 $10.75
9/15/202465,100 shares $777.29 thousand -14.6%1.1%2.4 $11.94
8/31/202476,200 shares $906.02 thousand -23.2%1.2%2.5 $11.89
8/15/202499,200 shares $1.25 million -1.5%1.6%2.7 $12.64
7/31/2024100,700 shares $1.31 million -11.7%1.5%2.6 $13.00
7/15/2024114,000 shares $1.43 million +2.2%2.6%1.7 $12.50
6/30/2024111,500 shares $1.33 million -1.9%2.6%1.6 $11.94
6/15/2024113,600 shares $1.53 million +5.8%2.6%1.5 $13.44
5/31/2024107,400 shares $1.36 million +53.2%2.5%1.5 $12.69
5/15/202470,100 shares $890.97 thousand -16.3%1.7%1 $12.71
A potential unicorn—still pre-IPO (Ad)

Mode Mobile - the company turning smartphones into EarnPhones - has posted $115M+ in revenue, 3-year growth of 32,481%, and an ecosystem of 490M+ users. With a Nasdaq ticker ($MODE) secured and Kevin Harrington of Shark Tank among early backers, the company is positioning for a potential IPO. Their previous two private raises sold out. Current pre-IPO shares are available at $0.50, with a 20% bonus - but this raise is on track to close soon.tc pixel

Review the pre-IPO offer details before this round closes
4/30/202483,700 shares $1.00 million +920.7%2.0%1.4 $11.98
4/15/20248,200 shares $135.25 thousand -95.8%N/A0.2 $16.49
3/31/2024195,400 shares $179.77 thousand +8.9%N/A0.3 $0.92
3/15/2024179,500 shares $122.94 thousand -18.9%N/A0.3 $0.68
2/29/2024221,400 shares $156.64 thousand -52.2%N/A0.3 $0.71
2/15/2024463,300 shares $320.74 thousand -22.1%N/A0.7 $0.69
1/31/2024594,500 shares $381.19 thousand -4.7%N/A0.9 $0.64
1/15/2024623,800 shares $477.83 thousand -38.8%N/A1.1 $0.77
12/31/20231,020,000 shares $809.88 thousand +44.3%N/A1.8 $0.79
12/15/2023707,100 shares $505.93 thousand -23.6%N/A1.3 $0.72
11/30/2023925,600 shares $656.62 thousand -24.8%N/A2.7 $0.71
11/15/20231,230,000 shares $953.25 thousand -0.8%N/A2.8 $0.78
10/31/20231,240,000 shares $951.08 thousand -6.1%N/A2.7 $0.77
10/15/20231,320,000 shares $1.21 million -12.0%N/A2.6 $0.92
9/30/20231,500,000 shares $1.41 million -3.9%N/A2.6 $0.94
9/15/20231,560,000 shares $1.67 million +31.1%N/A2.6 $1.07
8/31/20231,190,000 shares $933.08 thousand -16.2%N/A1.8 $0.78
8/15/20231,420,000 shares $1.29 million -8.4%N/A2.3 $0.91
7/31/20231,550,000 shares $1.54 million -4.9%N/A1.8 $1.00
7/15/20231,630,000 shares $1.79 million -6.9%N/A1.7 $1.10
6/30/20231,750,000 shares $1.98 million +17.5%N/A1.6 $1.13
6/15/20231,490,000 shares $1.70 million -22.0%N/A0.8 $1.14
5/31/20231,910,000 shares $2.54 million -14.0%N/A0.7 $1.33
5/15/20232,220,000 shares $3.02 million -7.9%N/A0.7 $1.36
4/30/20232,410,000 shares $2.46 million -21.8%N/A0.8 $1.02
4/15/20233,080,000 shares $3.33 million -13.2%N/A0.9 $1.08
3/31/20233,550,000 shares $4.51 million +63.6%N/A1 $1.27
3/15/20232,170,000 shares $3.65 million -30.0%N/A0.7 $1.68
2/28/20233,100,000 shares $4.68 million +56.6%N/A1.6 $1.51
2/15/20231,980,000 shares $3.15 million +13.1%N/A1.4 $1.59
1/31/20231,750,000 shares $2.15 million +141.3%N/A1.4 $1.23
1/15/2023725,200 shares $957.26 thousand +27.9%N/A1.2 $1.32
12/30/2022567,100 shares $428.90 thousand -7.1%N/A1.8 $0.76
12/15/2022610,200 shares $305.04 thousand +12.8%N/A2.2 $0.50
11/30/2022540,900 shares $346.23 thousand -25.3%N/A2.2 $0.64
11/15/2022724,300 shares $452.54 thousand +45.6%N/A3 $0.62
10/31/2022497,400 shares $305.90 thousand +22.7%N/A1.9 $0.62
10/15/2022405,300 shares $226.89 thousand -11.2%N/A0.9 $0.56
9/30/2022456,500 shares $286.68 thousand -23.2%N/A1 $0.63
9/15/2022594,400 shares $428.74 thousand -0.8%N/A1.2 $0.72
8/31/2022599,300 shares $407.52 thousand +38.8%N/A1.2 $0.68
8/15/2022431,800 shares $284.99 thousand -49.4%N/A0.8 $0.66
7/31/2022853,500 shares $670.00 thousand +58.8%N/A1.6 $0.79
7/15/2022537,500 shares $379.74 thousand +16.1%N/A1.6 $0.71
6/30/2022463,100 shares $226.27 thousand -16.0%N/A1.5 $0.49
6/15/2022551,100 shares $286.57 thousand -13.0%N/A1.8 $0.52
5/31/2022633,100 shares $291.23 thousand +18.9%N/A2.1 $0.46
5/15/2022532,400 shares $227.87 thousand -17.4%N/A2 $0.43
4/30/2022644,300 shares $449.01 thousand +16.9%N/A2.8 $0.70
4/15/2022551,400 shares $453.09 thousand +7.3%N/A2.1 $0.82
The chokepoint supplier behind SpaceX's $1.75 trillion empire (Ad)

When Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession. The world's largest supercomputer requires power equipment that takes 120 weeks to build, and Musk built Colossus in just 122 days. One small American company is positioned to close that gap faster than anyone else, yet Wall Street still prices it like an afterthought. Dylan Jovine has the full story and the ticker.tc pixel

See the stock Musk's own words pointed to right here
3/31/2022513,900 shares $427.92 thousand +2.5%N/A1.7 $0.83
3/15/2022501,500 shares $350.55 thousand -6.4%N/A1.3 $0.70
2/28/2022535,700 shares $374.99 thousand -9.7%N/A0.8 $0.70
2/15/2022593,300 shares $499.68 thousand -13.7%N/A0.8 $0.84
1/31/2022687,500 shares $620.74 thousand +25.4%N/A0.8 $0.90
1/15/2022548,100 shares $528.92 thousand -8.6%N/A0.6 $0.97
12/31/2021599,600 shares $761.49 thousand +18.8%N/A0.7 $1.27
12/15/2021504,700 shares $615.73 thousand -18.6%N/A0.6 $1.22
11/30/2021619,900 shares $923.65 thousand +33.2%N/A1.1 $1.49
11/15/2021465,500 shares $740.15 thousand -13.0%N/A0.9 $1.59
10/29/2021535,200 shares $845.62 thousand -7.9%1.2%1.2 $1.58
10/15/2021581,200 shares $976.42 thousand -14.3%1.3%1.4 $1.68
9/30/2021678,300 shares $1.52 million +4.0%2.0%1.8 $2.24
9/15/2021652,400 shares $1.36 million -6.1%1.9%1.6 $2.09
8/31/2021694,500 shares $1.60 million -8.9%2.0%1.7 $2.30
8/13/2021762,100 shares $1.28 million +7.4%2.2%2 $1.68
7/30/2021709,500 shares $1.08 million -13.2%2.1%1.8 $1.52
7/15/2021817,300 shares $1.36 million -14.4%2.4%1.9 $1.67
6/30/2021954,500 shares $1.93 million -40.7%2.8%2.1 $2.02
6/15/20211,610,000 shares $3.38 million -1.8%4.8%3 $2.10
5/28/20211,640,000 shares $3.31 million -4.1%4.9%3 $2.02

CDTX Short Interest - Frequently Asked Questions

Short interest is the volume of Cidara Therapeutics shares that have been sold short but have not yet been closed out or covered. As of December 31st, traders have sold 1,882,216 shares of CDTX short. 6.23% of Cidara Therapeutics' shares are currently sold short. Learn More on Cidara Therapeutics' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. CDTX shares currently have a short interest ratio of 2.2. Learn More on Cidara Therapeutics's short interest ratio.

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Cidara Therapeutics: Ikarian Capital LLC, Water Island Capital LLC, Tudor Investment Corp ET AL, Caption Management LLC, Balyasny Asset Management L.P., Boothbay Fund Management LLC, DV Equities LLC, and Equitec Proprietary Markets LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 6.23% of Cidara Therapeutics' floating shares are currently sold short.

Cidara Therapeutics saw a decrease in short interest in December. As of December 31st, there was short interest totaling 1,882,216 shares, a decrease of 6.8% from the previous total of 2,019,038 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

6.23% of Cidara Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Cidara Therapeutics: BioNTech SE Sponsored ADR (1.08%), Insmed, Inc. (6.93%), Moderna, Inc. (16.47%), Roivant Sciences Ltd. (4.24%), Viatris Inc. (3.25%), Genmab A/S Sponsored ADR (1.38%), Ascendis Pharma A/S (7.57%), Regencell Bioscience Holdings Limited (0.16%), Summit Therapeutics PLC (22.80%), BridgeBio Pharma, Inc. (14.30%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($68.76 billion), Invesco QQQ ($26.44 billion), iShares Russell 2000 ETF ($19.85 billion), iShares 20+ Year Treasury Bond ETF ($12.46 billion), AppLovin Corporation ($10.57 billion), SPDR S&P Biotech ETF ($9.48 billion), Palo Alto Networks, Inc. ($8.67 billion), Carvana Co. ($6.81 billion), Western Digital Corporation ($6.35 billion), and iShares MSCI Emerging Markets ETF ($6.03 billion). View all of the most shorted stocks.

Short selling CDTX is an investing strategy that aims to generate trading profit from Cidara Therapeutics as its price is falling. CDTX shares are trading up $0.06 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Cidara Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CDTX, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CDTX, twice per month. The most recent reporting period available is December, 31 2025.

Understanding short interest metrics can help you assess how traders are positioning around a stock like CDTX:

  • Shares Sold Short: The total number of shares that have been sold by short sellers but have not yet been covered or closed out. A high number may indicate bearish sentiment.
  • Short Float: The percentage of a company’s publicly available shares (or "float") that are sold short. A higher short float suggests a greater portion of the stock is being bet against.
  • Days to Cover (Short Interest Ratio): This estimates how many days it would take short sellers to cover their positions, based on average daily trading volume. Higher values can signal potential for a short squeeze if buying pressure increases.

These metrics are often used by traders to gauge sentiment, volatility risk, and the potential for price movements based on short covering activity.


Related Companies
Short Interest Tools

This page (NASDAQ:CDTX) was last updated on 5/18/2026 by MarketBeat.com Staff.
From Our Partners
Musk’s warning just revealed a $1T opportunity
Elon Musk recently warned that AI could force governments to introduce universal income. Mode Mobile isn't wai...
Mode Mobile | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
ZENA Surges: 558% Revenue Growth Fuels Breakout Small-Cap Narrative!
ZenaTech (NASDAQ: ZENA) reported $12.9 million in full-year 2025 revenue, representing 558% year-over-year gro...
Equiscreen | Sponsoredtc pixel
BNZI Update: Zacks Buy Rating Sparks Fresh Momentum!
Banzai International (NASDAQ: BNZI) delivered full-year 2025 revenue of $12.2 million, a 169% year-over-year i...
Huge Alerts | Sponsoredtc pixel
This next market event could mean total financial ruin for some
A market signal last detected before the Great Depression may be flashing again - and according to Weiss Ratin...
Weiss Ratings | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
BlackRock's $100B Secret
At any given time, BlackRock manages anywhere from $60-100 billion in Bitcoin. But they're not paying retail p...
Decentralized Masters | Sponsoredtc pixel